

In response to the further requirement for election of a single disclosed species, applicants elect the species of example 14A, the structure of which is shown on page 62 of the specification.


Comments on aspects of the restriction requirement

Restriction group I is defined as claims 1-3, 6-8, 11-13, and 16 (all in part), relating to compounds and pharmaceutical compositions containing them in which Z is nitrogen, and R1 and R2 form a bridged substituent with heteroatoms in the second ring thus formed. Applicants point out that this definition does not apply to claims 11-13 because in these claims, Z is defined as CR<sup>4</sup>, not N.

Restriction group II is defined as claims 1-3, 6-8, 11-13, and 16 (all in part), relating to compounds and pharmaceutical compositions containing them in which Z is nitrogen, and R1 and R2 form a bridged substituent without heteroatoms in the second ring thus formed. Applicants point out that this definition does not apply to claims 11-13 because in these claims, Z is defined as CR<sup>4</sup>, not N.

Restriction group III is defined as claims 6-8 and 11-13 (all in part), relating to compounds and pharmaceutical compositions containing them in which Z is nitrogen and R1 and R2 do not form a bridge. Applicants point out that this definition does not apply to claims 11-13 because in these claims, Z is defined as CR<sup>4</sup>, not N.

Respectfully submitted,



William F. Gray  
Bayer HealthCare LLC  
400 Morgan Lane  
West Haven, CT 06516-4175

Reg. No. 31018  
Phone: (203) 812-2712  
Date: 25 February 2008